New eye drops offer an alternative to reading glasses. People with mild to moderate presbyopia, or age-related farsightedness, may no longer have to rely on their reading glasses to read a book or a menu. In early December, new eye drops, pilocarpine hydrochloride ophthalmic solution, marketed as Vuity, became available to consumers. According to Allergan, the manufacturer, Vuity is the first drug approved by the Food and Drug Administration to treat presbyopia. Others are in clinical trials and likely to be available soon. Presbyopia typically starts at about 40 years of age and affects over a billion people worldwide, including 128 million Americans. Vuity works by constricting pupil size, creating a pinhole effect that increases the ability to focus on near objects without affecting distance vision. The medication is approved for use once a day and usually takes effect within 15 minutes, lasting about six hours.